Ablation as ‘first-line’ therapy
Post-hoc analysis of ablation therapy as ‘first-line therapy’ prior to initiation of Class I/III anti-arrhythmic agents showed similar outcomes. The AVATAR arm had significantly fewer primary endpoints [14 patients (21% of 67 Class I/III naïve patients) vs. 44 patients (70% of 63 Class I/III naïve patients), 